1 / 67

IMMUNOMODULATORS

IMMUNOMODULATORS. Dr. Manjunath . The Immune Response - why and how ?. Discriminate: Self / Non self Destroy: Infectious invaders Dysregulated self (cancers) Immunity: Innate, Natural Adaptive, Learned . Innate Complement Granulocytes Monocytes/macrophages NK cells Mast cells

maureen
Download Presentation

IMMUNOMODULATORS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IMMUNOMODULATORS Dr. Manjunath

  2. The Immune Response - why and how ? • Discriminate: Self / Non self • Destroy: • Infectious invaders • Dysregulated self (cancers) • Immunity: • Innate, Natural • Adaptive, Learned

  3. Innate Complement Granulocytes Monocytes/macrophages NK cells Mast cells Basophils Adaptive: B and T lymphocytes B: antibodies T : helper, cytolytic, suppressor. Who are involved ?

  4. Immunosuppressants Immunostimulants IMMUNE MODIFIERS ? Immune tolerance

  5. Immunosuppressants • Glucocorticoids • Calcineurin inhibitors • Cyclosporine • Tacrolimus • Antiproliferative / antimetabolic agents • Sirolimus • Everolimus • Azathioprine • Mycophenolate Mofetil • Others – methotrexate, cyclophosphamide, thalidomide and chlorambucil

  6. Antibodies • Antithymocyte globulin • Anti CD3 monoclonal antibody • Muromonab • Anti IL-2 receptor antibody – • Daclizumab, basiliximab • Anti TNF alpha – infliximab, etanercept

  7. Immunostimulants • Levamisole • Thalidomide • BCG • Recombinant Cytokines • Interferons • Interleukin-2

  8. Organ transplantation Autoimmune diseases Life long use Infection, cancers Nephrotoxicity Diabetogenic Immunosuppressants Problem

  9. Glucocorticoids • Induce redistribution of lymphocytes – decrease in peripheral blood lymphocyte counts • Intracellular receptors – regulate gene transcription • Down regulation of IL-1, IL-6 • Inhibition of T cell proliferation • Neutrophils, Monocytes display poor chemotaxis • Broad anti-inflammatory effects on multiple components of cellular immunity

  10. USES - Glucocorticoids • Transplant rejection • GVH – BM transplantation • Autoimmune diseases – RA, SLE, Hematological conditions • Psoriasis • Inflammatory Bowel Disease, Eye conditions

  11. Toxicity • Growth retardation • Avascular Necrosis of Bone • Risk of Infection • Poor wound healing • Cataract • Hyperglycemia • Hypertension

  12. Calcineurin inhibitors • Cyclosporine • Tacrolimus • Most effective immunosuppressive drugs • Target intracellular signaling pathways • Blocks Induction of cytokine genes

  13. Cyclosporine • More effective against T-cell dependent immune mechanisms – transplant rejection, autoimmunity • IV, Oral Uses • Organ transplantation: Kidney, Liver, Heart • Rheumatoid arthritis, IBD, uveitis • Psoriasis • Aplastic anemia • Skin Conditions- Atopic dermatitis, Alopecia Areata, Pemphigus vulgaris, Lichen planus, Pyoderma gangrenosum

  14. Toxicity : Cyclosporine • Renal dysfunction • Tremor • Hirsuitism • Hypertension • Hyperlipidemia • Gum hyperplasia • Hyperuricemia – worsens gout • Calcineurin inhibitors + Glucocorticoids = Diabetogenic

  15. Drug Interaction : Cyclosporine • CYP 3A4 • Inhibitors: CCB, Antifungals, Antibiotics, HIV PI, Grape juice • Inducers: Rifampicin, Phenytoin • Additive nephrotoxicity: NSAIDs

  16. Tacrolimus • Inhibits T-cell activation by inhibiting calcineurin • Use • Prophylaxis of solid-organ allograft rejection

  17. Toxicity - Tacrolimus • Nephrotoxicity • Neurotoxicity-Tremor, headache, motor disturbances, seizures • GI Complaints • Hypertension • Hyperglycemia • Risk of tumors, infections • Drug interaction • Synergistic nephrotoxicity with cyclosporine • CYP3A4

  18. Antiproliferative and Antimetabolic drugs • Sirolimus • Everolimus • Azathioprine • Mycophenolate Mofetil • Others: • Methotrexate • Cyclophosphamide • Thalidomide • Chlorambucil

  19. Sirolimus • Inhibits T-cell activation and Proliferation • Complexes with an immunophilin, Inhibits a key enzyme in cell cycle progression – mammalian target of rapamycin (mTOR)

  20. Sirolimus Uses • Prophylaxis of organ transplant rejection along with other drugs Toxicity • Increase in serum cholesterol, Triglycerides • Anemia • Thrombocytopenia • Hypokalemia • Fever • GI effects • Risk of infection, tumors • Drug Interactions: CYP 3A4

  21. Everolimus • Shorter half life compared to sirolimus • Shorter time taken to reach steady state • Similar toxicity, drug interactions

  22. Azathioprine • Purine antimetabolite • Incorporation of false nucleotide 6 Thio-IMP 6Thio-GMP 6Thio-GTP • Inhibition of cell proliferation • Impairment of lymphocyte function Uses • Prevention of organ transplant rejection • Rheumatoid arthritis

  23. Toxicity - Azathioprine • Bone marrow suppression- leukopenia, thrombocytopenia, anemia • Increased susceptibility to infection • Hepatotoxicity • Alopecia • GI toxicity • Drug interaction: Allopurinol

  24. Mycophenolate Mofetil • Prodrug  Mycophenolic acid • Inhibits IMPDH – enzyme in guanine synthesis • T, B cells are highly dependent on this pathway for cell proliferation • Selectively inhibits lymphocyte proliferation, function – Antibody formation, cellular adhesion, migration

  25. Uses - Mycophenolate Mofetil • Prophylaxis of transplant rejection • Combination: Glucocorticoids Calcineurin Inhibitors • Toxicity • GI, Hematological • Diarrhea, Leucopenia • Risk of Infection

  26. Drug Interaction • Decreased absorption when co-administered with antacids • Acyclovir, Gancyclovir compete with mycophenolate for tubular secretion

  27. FTY720 • S1P-R agonist – sphingosine 1 receptor • Reduce recirculation of lymphocytes from lymphatic system to blood and peripheral tissues • “Lymphocyte homing” – periphery into lymph node • Protects graft from T-cell-mediated attack Uses • Combination immunosuppression therapy in prevention of acute graft rejection

  28. Toxicity • Lymphopenia • Negative chronotropic effect • S1P-receptor on human atrial myocytes

  29. Antibodies • Against lymphocyte cell-surface antigens • Polyclonal / Monoclonal

  30. Antibodies • Antithymocyte Globulin • Monoclonal antibodies • Anti-CD3 Monoclonal antibody (Muromonab-CD3) • Anti-IL-2 Receptor antibody (Daclizumab, Basiliximab) • Campath-1H (Alemtuzumab) • Anti-TNF Agents • Infliximab • Etanercept • Adalimumab • LFA-1 Inhibitor (lymphocyte function associated) • Efalizumab

  31. Anti-thymocyte Globulin • Purified gamma globulin from serum of rabbits immunized with human thymocytes • Cytotoxic to lymphocytes & block lymphocyte function Uses • Induction of immunosuppression – transplantation • Treatment of acute transplant rejection Toxicity • Hypersensitivity • Risk of infection, Malignancy

  32. Anti-CD3 Monoclonal Antibody • Muromonab-CD3 • Binds to CD3, a component of T-cell receptor complex involved in • antigen recognition • cell signaling & proliferation

  33. Muromonab-CD3 Antibody treatment Rapid internalization of T-cell receptor Prevents subsequent antigen recognition

  34. Uses • Treatment of acute organ transplant rejection Toxicity • “Cytokine release syndrome” • High fever, Chills, Headache, Tremor, myalgia, arthralgia, weakness • Prevention: Steroids

  35. Anti-IL-2 Receptor Antibodies • Daclizumab and Basiliximab • Bind to IL-2 receptor on surface of activated T cells  Block IL-2 mediated T-cell activation Uses • Prophylaxis of Acute organ rejection Toxicity • Anaphylaxis, Opportunistic Infections

  36. Campath-1H (Alemtuzumab) • Targets CD52 – expressed on lymphocytes, monocytes, Macrophages • Extensive lympholysis – Prolonged T & B cell depletion Uses • Renal transplantation

  37. Anti-TNF Agents • TNF – Cytokine at site of inflammation • Infliximab • Etanercept • Adalimumab

  38. Infliximab Uses • Rheumatoid arthritis • Chron’s disease – fistulae • Psoriasis • Psoriatic arthritis • Ankylosing spondylosis Toxicity • Infusion reaction – fever, urticaria, hypotension, dyspnoea • Opportunistic infections – TB, RTI, UTI

  39. Etanercept • Fusion protein • Ligand binding portion of Human TNF-α receptor fused to Fc portion of human IgG1 Uses • Rheumatoid arthritis

  40. moderate to severely active crohn’s disease Adalimumab Recombinant human anti-TNF mAb

  41. LFA-1 Inhibitor - Efalizumab • Monoclonal Ab Targeting Lymphocyte Function Associated Antigen • Blocks T-cell Adhesion, Activation, Trafficking Uses • Organ transplantation • Psoriasis

  42. Sites of Action of Selected Immunosuppressive Agents on T-Cell Activation DRUG SITE OF ACTION • Glucocorticoids Glucocorticoid response elements in DNA (regulate gene transcription) • Muromonab- CD3T-cell receptor complex (blocks antigen recognition) • Cyclosporine Calcineurin (inhibits phosphatase activity) • Tacrolimus Calcineurin (inhibits phosphatase activity) • Azathioprine Deoxyribonucleic acid (false nucleotide incorporation) • Mycophenolate Mofetil Inosine monophosphate dehydrogenase (inhibits activity) • Daclizumab, Basiliximab IL-2 receptor (block IL-2-mediated T-cell activation) • Sirolimus Protein kinase involved in cell-cycle progression (mTOR) (inhibits activity)

More Related